Siemens Healthineers has introduced its latest diabetes care innovation, the next-generation point-of-care Atellica DCA Analyser. Designed to optimise diabetes management and enable early diagnosis, the analyser empowers clinicians to conduct HbA1c and ACR testing at the point of care, delivering results within minutes. With diabetes cases on the rise, early detection and management are critical yet nearly half of people with diabetes are undiagnosed.1 The Atellica DCA Analyser addresses key challenges such as large patient volumes and limited space, ensuring patients receive timely medical guidance and helping to remove the need for additional appointments.
Used for diagnosing and monitoring diabetes, the compact Atellica DCA Analyser produces HbA1c and ACR results in minutes and provides flexibility both in its design and workflow capabilities. Possessing a small footprint while maintaining the accuracy of central laboratory methods, the Atellica DCA Analyser is suitable for any testing environment. Clinicians can deliver care with confidence as proprietary Auto-Checks Technology runs internal checks and system calibrations throughout the analysis process to safeguard against sample loss and erroneous results. The analyser can also seamlessly transmit data via Wi-Fi or Ethernet to the provider’s LIS/HIS/EMR.
“Diabetes cases are rising, with estimates suggesting more than 780 million cases by 2045. By diagnosing early, we can help to prevent the health complications that occur when chronic conditions are left unmanaged," states Tobias Livingstone, Point of Care Business Lead at Siemens Healthineers Great Britain & Ireland. “The Atellica DCA Analyser enables HbA1c testing in a single interaction, supporting optimal diabetes management. This also minimises the barriers to care that patients may otherwise face if they needed to return to for further medical guidance after traditional testing."
More information on the Atellica DCA Analyser can be found here.